The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors
Abstract
Recombinant factor VIIa (rFVIIa) was developed to provide an improved procoagulant component capable of ‘by‐passing’ inhibitor antibodies in the treatment of haemophilic patients. The primary objective of this study was to compare the efficacy of two dosage regimens of rFVIIa (given intravenously at periodic intervals) in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B with and without inhibitors. The study was designed as a randomized, double‐blind, parellel group, international multicenter trial. Patients were randomly allocated to treatment A: 35 μ kg−1 or B:␣70 μ kg−1, in blocks of 2. Within each block, one patient was assigned to the 35 μ kg−1 dosing regimen and the other to 70 μ kg−1 dose. One hundred and fifty subjects from 20 sites were screened for this study and 116 had baseline assessments. Of these, 84 were treated on the protocol and 32 were not treated in the study, in most cases because they did not return to the clinic with an eligible bleeding episode. One hundred and seventy‐nine bleeding episodes were treated, of which 145 (81%) were acute haemarthroses. Both treatments were efficacious, with 71% having an excellent (59% and 60%) or effective (12% and 11%) response. Overall, the mean and median number of doses given per episode of joint bleeding were 3.1 and 2, respectively. The mean number of doses was 3.1 for the 70 μ kg−1 group and 2.7 for the 35 μ kg−1 group (P value = 0.142). The study concluded that rFVIIa in a dosage of 35 μ kg−1 or 70 μ kg−1 is both safe and reasonably effective in the treatment of joint or muscle haemorrhages in haemophilic patients with inhibitor antibodies to factor VIII or factor IX. It is concluded that the appropriate dose for the treatment of joint and peripheral muscle bleeding in haemophilic patients with inhibitors is 35–70 μ kg−1 given at 2–3 h intervals until haemostasis is achieved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280701 · Cited by 476
Cited by
Hay, C. R. M., Brown, S., Collins, P. W., Keeling, D. M., & Liesner, R. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06087.x · Cited by 327
Abshire, T., & Kenet, G. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00759.x · Cited by 314
Aledort, L. M. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00944.x · Cited by 286
The use of recombinant factor VIIa in the treatment of bleeding disorders
Roberts, H. R., Monroe, D. M., & White, G. C. (2004) · Blood · doi:10.1182/blood-2004-06-2223 · Cited by 275
Metadata
- Authors
- Lusher, Roberts, Davignon, Joist, Smith, Shapiro, Laurian, Kasper, Mannucci, & rFVIIa Study Group
- Venue
- Haemophilia
- Publisher
- Wiley
- Published
- 1998-11
- Volume
- 4
- Issue
- 6
- Pages
- 790-798
- ISSN
- 1351-8216 (ISSN-L)
- 1365-2516
- OpenAlex
- W1997685722
- Cited by
- 212
- References
- 1
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. https://app.cochat.ai/papers/10.1046/j.1365-2516.1998.00209.x
- The paper
- Lusher, Roberts, Davignon, Joist, Smith, Shapiro, Laurian, Kasper, Mannucci, & rFVIIa Study Group. (1998). A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. https://doi.org/10.1046/j.1365-2516.1998.00209.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.